Diagnosis
Challenges exist to diagnosing CIDP,2,8-12 so patients experience median delays of 10 months (range 2-64 months), which could be longer for patients with CIDP variants.9 CIDP diagnosis may be incorrect or delayed due to variations in diagnostic criteria and the existence of stringent electrodiagnostic criteria established for clinical trial screening, which may not capture all patients who could respond to treatment2. Diagnostic criteria for CIDP have been difficult to develop because of disease heterogeneity and variation in disease progression, including non-uniform nerve demyelination, debates on the definition of nerve demyelination, and a lack of diagnostic biomarkers.10
Due in part to the absence of a diagnostic biomarker, and the fact that CIDP is one of the few treatable causes of neuropathy, numerous diagnostic criteria have been developed for CIDP, with the goal of identifying the maximum number of patients for treatment.4,11,13-15
Fifteen formal sets of clinical diagnostic criteria have been published for use in CIDP.11 Four of the most prominent guidelines are from the European Academy of Neurology/Peripheral Nerve Society (EAN/PNS),4 the Inflammatory Neuropathy Cause and Treatment (INCAT) group,13 the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM)16 and the American Academy of Neurology (AAN).17
Although specific diagnostic criteria vary, there is general agreement that clinical and electrophysiologic features are the most important in making an accurate diagnosis.4,11,13-15 Supportive laboratory assessments are used where clinical and electrodiagnostic criteria are not fulfilled.4 Diagnosis is given alongside one of two levels of certainty: CIDP or possible CIDP.4 There is consensus among the different sets of criteria that patients should have reduced or absent reflexes and that the development of motor/sensory dysfunction should manifest over at least 2 months.5,12,14,16 Four of the most prominent sets of criteria differ in terms of electrodiagnostic–test result requirements.4,13,15,17 This may be due to the growing understanding of CIDP as a heterogenous disease.
Updates to the guidelines in 2021 include: the term ‘CIDP variants’ replacing ‘atypical CIDP’, and the number of levels of diagnostic uncertainty decreasing from three (‘definite’, ‘probable’ or ‘possible’) to two (‘definite’ or ‘possible’).4,15 Several neuropathies need to be excluded to make a positive diagnosis of typical CIDP, as listed below:4
- Motor and sensory symptoms
- Paresthesia
- Difficulty walking
- Progressive symmetric proximal and distal muscle weakness, sensory loss, decreased/absent deep tendon reflexes